3-weekly Daratumumab-IMiD-dexamethasone is highly efficacious and cost-effective in relapsed/refractory multiple myeloma
| Autor: | Chim, James, Wong, V.K., Au, Eyl, Kwong, Yok Lam |
|---|---|
| Zdroj: | In Clinical Lymphoma, Myeloma and Leukemia October 2019 19(10) Supplement:e251-e251 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect